- Design
- Multicentre cross-sectional online survey
- Population
- 296 people alive more than 5 years after stage IV melanoma, 40 centres
- Primary outcome
- Persistent treatment effects, distress and financial burden
- Effect
- About 40% persistent effects; 40% raised distress; persistent effects vs distress OR 1.99
This cross-sectional survey, published in the British Journal of Dermatology on 19 September, reached 296 people alive more than five years after a stage IV melanoma diagnosis, through 40 centres in Germany, Austria and Switzerland. About 80% had received immune checkpoint inhibitors and 27% targeted therapy; about 30% had had brain metastases.
About 40% reported persistent treatment-related adverse effects and about 40% had distress above the screening threshold. Persistent effects of systemic therapy were associated with raised distress (OR 1.99). Cognitive problems after brain radiotherapy and lymphoedema after surgery were the commonest complaints. About 23% reported financial strain, and 44% of retirees had stopped work early because of melanoma.
More patients now live long after metastatic melanoma, and routine oncology follow-up is built around recurrence. This survey suggests survivorship care needs to screen actively for lasting physical, cognitive, psychological and financial harms.
- At follow-up, ask about persistent treatment effects, not only recurrence.
- Screen for distress with a validated tool; four in ten were above threshold.
- Ask about memory and concentration after brain radiotherapy.
- Check for lymphoedema after nodal surgery and refer early.
- Ask about work and money; one in four reported financial strain.
Why it matters
Survival after stage IV melanoma is now common enough that its costs need a clinic of their own.
Don't overread it
Survey respondents may not represent all survivors; those with more problems may be likelier to answer.
The statistics, in plain English
An odds ratio of 1.99 means survivors with persistent side effects had about twice the odds of raised distress. It shows an association in one survey, not that the side effects caused the distress.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free